Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-09-15 19:11:48 ET · period of report 2026-09-15 · accession 0000907654-26-000094 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 19:11 | 2026-09-15 | ORKA | Sandler Laura Lee | COO | S - Sale | $95.71 | -906 | 235.5K | -0.4% | -$86.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | S | D | 906 | $95.71 | 235,478 | D | — | — | (F1) The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |